



FINAL REPORT

Bill No.	: MGMWPR240094350	Bill Date	: 19-10-2024 12:26
Patient Name	: MR. KIRAN BHAGWAN TAWARE	UHID	: MGM240017131
Age / Gender	: 56 Yrs 2 Mth / MALE	Patient Type	: IPD If PHC :
Ref. Consultant	: DR.PRASHANT ATHALE	Ward	: SICU
Sample ID	: MGM24156996	Current Bed	: SICU-011
IP Number	: MGMIP2406720	Reporting Date & Time	: 22-10-2024 14:17
		Receiving Date & Time	: 19/10/2024 12:42

Microbiology Report

BLOOD - C/S - 2 - BAC ALERT

Specimen : Blood
Site : Peripheral & Femoral site

Organism : Escherichia coli

ANTIBIOTICS	INTERPRETATION	MIC
Amikacin	SENSITIVE	4
Amoxicillin/Clavulanic acid	INTERMEDIATE	16
Cefotaxime	RESISTANT	Disc diffusion
Ceftriaxone	RESISTANT	>=64
Cefuroxime	RESISTANT	>=64
Cefoperazone	RESISTANT	Disc diffusion
Ceftazidime	RESISTANT	Disc diffusion
Gentamicin	RESISTANT	>=16
Netilmicin	SENSITIVE	Disc diffusion
Ciprofloxacin	RESISTANT	>=4
Ofloxacin	RESISTANT	Disc diffusion
Levofloxacin	RESISTANT	Disc diffusion
Trimethoprim/Sulphamethoxazole	SENSITIVE	<=20
Piperacillin/Tazobactam	SENSITIVE	<=4
Cefepime	RESISTANT	16
Imipenem	SENSITIVE	<=0.25
Meropenem	SENSITIVE	<=0.25
Cefaperazone/Sulbactam	SENSITIVE	<=8
Ticarcillin/Clavulanic acid	SENSITIVE	Disc diffusion
Cefuroxime Axetil	RESISTANT	>=64

Method :- Culture- Aerobic by Automated BACT/ ALERT 3D. Identification done by Biochemical reactions / Automated Vitek-2 .
Antimicrobial sensitivity by automated Vitek -2 / conventional methods/estrips.

Note :-

1. Result of culture and antimicrobial susceptibility test need to be correlated clinically.
2. Previous history of antibiotic usage may influence the growth of microorganisms in vitro.
3. Antibiotic susceptibility done as per revised CLSI Guidelines.

Clinical Reference :

1. CLSI: Performance standards for Antimicrobial Susceptibility Testing.

*****End of the Report*****